UY37560A - Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta - Google Patents

Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta

Info

Publication number
UY37560A
UY37560A UY0001037560A UY37560A UY37560A UY 37560 A UY37560 A UY 37560A UY 0001037560 A UY0001037560 A UY 0001037560A UY 37560 A UY37560 A UY 37560A UY 37560 A UY37560 A UY 37560A
Authority
UY
Uruguay
Prior art keywords
mcl
inhibitor
combination
compound
taxan
Prior art date
Application number
UY0001037560A
Other languages
English (en)
Inventor
Dale Porter
Ensar Halilovic
Leticia Maragno Ana
Chanrion Maïa
Olivier Geneste
Delphine Merino
James Whittle
VAILLANT François
Jane Visvader
Geoffrey Lindeman
Guillaume Lessene
Elisabetta Marangoni
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of UY37560A publication Critical patent/UY37560A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Una combinación que comprende un inhibidor de MCL-1 y un compuesto taxano, y composiciones y usos de ésta.
UY0001037560A 2017-01-06 2018-01-04 Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta UY37560A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443082P 2017-01-06 2017-01-06
EP17157779 2017-02-24
US201762527360P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
UY37560A true UY37560A (es) 2018-07-31

Family

ID=58158963

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037560A UY37560A (es) 2017-01-06 2018-01-04 Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta

Country Status (3)

Country Link
TW (1) TWI674898B (es)
UY (1) UY37560A (es)
WO (1) WO2018127575A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020003180A2 (pt) 2017-08-15 2020-09-15 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
WO2020123994A1 (en) * 2018-12-14 2020-06-18 Prelude Therapeutics, Incorporated 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as mcl-1 enzyme inhibitors for treating cancer
TW202114682A (zh) * 2019-06-17 2021-04-16 法商施維雅藥廠 Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
CA3222269A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051305B2 (en) * 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN105311016A (zh) * 2014-07-24 2016-02-10 中国科学院大连化学物理研究所 一种抗细胞凋亡Mcl-1蛋白抑制剂及其应用
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TWI674898B (zh) 2019-10-21
WO2018127575A1 (en) 2018-07-12
TW201828942A (zh) 2018-08-16

Similar Documents

Publication Publication Date Title
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CR20170099A (es) Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201992177A1 (ru) Композиции на основе нирапариба
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MD3347360T2 (ro) Compuși utili pentru inhibarea ROR-gama-t
ECSP19006687A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl-1, usos y composiciones farmacéuticas de éstos
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CY1124258T1 (el) ΕΝΩΣΕΙΣ ΧΡΗΣΙΜΕΣ ΓΙΑ ΑΝΑΣΤΟΛΗ ROR-γ-t
CL2019001859A1 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
CL2018000489A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
CU20170134A7 (es) 2-tiopirimidinonas
CY1124177T1 (el) Ενωσεις χρησιμες για την αναστολη του ror-γαμμα-τ
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EA201991623A1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
EA201990305A1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
BR112016022439A2 (pt) Composições farmacêuticas que compreendem cefepima ou sulbactama
AR111177A1 (es) Composiciones farmacéuticas que comprenden un inhibidor de jak